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Abstract  1 
Computerized clinical decision support systems can help to provide objective, standardized, 2 
and timely dementia diagnosis. However, current computerized systems are mainly based on 3 
group analysis, discrete classification of disease stages, or expensive and not readily 4 
accessible biomarkers, while current clinical practice relies relatively heavily on cognitive and 5 
functional assessments (CFA). In this study, we developed a computational framework using 6 
a suite of machine learning tools for identifying key markers in predicting the severity of 7 
Alzheimer’s disease (AD) from a large set of biological and clinical measures. Six machine 8 
learning approaches, namely Kernel Ridge Regression (KRR), Support Vector Regression, 9 
and k-Nearest Neighbor for regression and Support Vector Machine (SVM), Random Forest, 10 
and k-Nearest Neighbor for classification, were used for the development of predictive models. 11 
We demonstrated high predictive power of CFA. Predictive performance of models 12 
incorporating CFA was shown to consistently have higher accuracy than those based solely 13 
on biomarker modalities. We found that KRR and SVM were the best performing regression 14 
and classification methods respectively. The optimal SVM performance was observed for a 15 
set of four CFA test scores (FAQ, ADAS13, MoCA, MMSE) with multi-class classification 16 
accuracy of 83.0%, 95%CI = (72.1%, 93.8%) while the best performance of the KRR model 17 
was reported with combined CFA and MRI neuroimaging data, i.e., R2 = 0.874, 95%CI = 18 
(0.827, 0.922). Given the high predictive power of CFA and their widespread use in clinical 19 
practice, we then designed a data-driven and self-adaptive computerized clinical decision 20 
support system (CDSS) prototype for evaluating the severity of AD of an individual on a 21 
continuous spectrum. The system implemented an automated computational approach for 22 
data pre-processing, modelling, and validation and used exclusively the scores of selected 23 
cognitive measures as data entries. Taken together, we have developed an objective and 24 
practical CDSS to aid AD diagnosis.  25 
Keywords: dementia; Alzheimer’s disease; decision support system; machine learning; 26 
diagnosis support; cognitive impairment  27 
1. Introduction  28 
Recent advances in machine learning (ML) and big data analytics have led to the emergence 29 
of a new generation of clinical decision support systems (CDSSs) designed to exploit the 30 
potentials of data-driven decision making in patient monitoring, particularly in the area of 31 
internal medicine, general practice, and remote monitoring of vital signs (Gálvez et al., 2013, 32 
Helldén et al., 2015 Lisboa & Taktak, 2006, Skyttberg, Vicente, Chen, Blomqvist, & Koch, 33 
2016). Improved access to large and heterogeneous healthcare data and an integration of 34 
advanced computational procedures into CDSSs has enabled the real-time discovery of 35 
similarity metrics for patient stratification, development of predictive analytics for risk 36 
assessment, and selection of patient-specific therapeutic interventions at the time of decision-37 
making (Brown, 2016, Dagliati et al., 2018, Farran, Channanath, Behbehani, & Thanaraj, 38 
2013). CDSSs provide clinical decision support at the time and location of care rather than 39 
prior to or after the patient encounter and therefore, help streamline the workflow for clinicians 40 
and assist real-time decision-making (diagnosis, prognosis, treatment) (Castaneda et al., 41 
2015, Wright et al., 2016). Numerous studies demonstrated that CDSSs contributed to 42 
improving patient safety and care by decreasing the number of therapeutic and diagnostic 43 
errors that are unavoidable in human clinical practice (Lindquist, Johansson, Petersson, 44 
Saveman, & Nilsson, 2008) and reduced the workload of medical staff, especially in contexts 45 
that require frequent monitoring or complex decision-making, such as management of chronic 46 
diseases (Wright et al., 2016). Current research directions in dementia, with Alzheimer’s 47 
disease (AD) being its most common form, focuses on interventions and treatments that can 48 
modify progression of dementia symptoms or lead to an early identification of individuals at 49 
risk of developing dementia (Brodaty et al., 2016, Ritchie et al., 2017). Increasing evidence 50 
suggests that early diagnosis of dementia can lead to significant clinical and economic 51 
benefits. However, the underdiagnosis of dementia is currently one of the key deficiencies in 52 
disease management in the primary care setting (Dodd, Cheston, & Ivanecka, 2015, Lang et 53 
al., 2017, Paterson & Pond, 2009). Research indicates that low dementia detection rates in 54 
primary care are mainly related to the absence of standardized and reliable screening tools, 55 
inadequate training on dementia of general practitioners (GPs), and the GPs' lack of 56 
confidence in providing a correct diagnosis (Koch, Iliffe, & EVIDEM-ED project, 2010).  57 
Technology-based tools have considerable potential to transform the dementia care pathway. 58 
CDSS utilized in the early diagnosis of AD may allow for the selection of patients for clinical 59 
trials at the earliest possible stage of disease development and enable clinicians to initiate the 60 
treatment as early in the disease process as possible to more effectively arrest or slow disease 61 
progression. A number of applications have been developed to serve as enabling tools for 62 
dementia diagnostics (Mandala, Saharana, Khana & Jamesa, 2015). These include software 63 
applications that provide practical information for those caring for dementia patients (e.g., 64 
Dementia Support by Swedish Care International, Alzheimer’s and Other Dementias Daily 65 
Companion, MindMate) as well as tools used for mobile cognitive screening (e.g., MOBI-COG, 66 
Mobile Cognitive Screening, Dementia Screener, Sea Hero Quest, CANTAB). In addition, 67 
CDSSs, designed to aid clinical decision making by adapting computerized clinical practice 68 
guidelines to individual patient characteristics or integrating machine learning methodologies 69 
for pattern recognition, have been recently gaining more interest in expediting dementia 70 
diagnosis and disease management (Antila et al., 2013, Frame, LaMantia, Bynagari, Dexter, 71 
& Boustani, 2013, Lindgren, 2011, Lindgren, Eklund, & Eriksson, 2002). It has been shown 72 
that such systems are more sensitive in detecting an early-stage disease and more objective 73 
than diagnostic decisions made by a single practitioner (Moja et al., 2015).  74 
Despite the fact that advanced computational approaches for AD classification and 75 
progression have been applied to large sets of patient data, including magnetic resonance 76 
imaging (MRI) (Karas et al., 2008, Lebedeva et al., 2017, Moradi et al., 2015), positron 77 
emission tomography (PET) (Higdon et al., 2004, Grimmer et al., 2016, Sanchez-Catasus et 78 
al., 2017), cerebrospinal fluid (CSF) biomarkers (Forlenza et al., 2015, Handels et al., 2017, 79 
Mattsson et al., 2009), combination of the neuroimaging modalities (Youssofzadeh, 80 
McGuinness, Maguire, & Wong-Lin., 2017), and cognitive and functional assessments (CFA) 81 
(Ding et al., 2018, Chapman et al., 2011, Korolev, Symonds, Bozoki & Alzheimer's Disease 82 
Neuroimaging Initiative, 2016, Maroco et al., 2011), there is a significant gap between 83 
research outputs and their actual utilization in daily clinical practice. In contrast to other 84 
disease areas, the integration of machine learning methodologies into CDSSs and their 85 
deployment for a routine use in AD diagnostics is still very rare. The few systems that are used 86 
in dementia diagnostics require information from expensive and labour-intensive biomarkers 87 
(Antila et al., 2013, Soininen et al., 2012) or implement predictive methodologies based on 88 
discrete classes for the different stages of the disease even if the underlying neurobiology 89 
could possibly evolve in a continuous manner (Onoda & Yamaguchi, 2014). Furthermore, to 90 
the best of our knowledge, no CDSS for dementia detection or management has been 91 
developed so far for the use in the primary care setting. 92 
The aim of this study is two-fold: (1) to describe the developmental process of a computational 93 
framework for identifying key measures in predicting the severity of AD; and (2) to build upon 94 
this framework to develop a data-driven and self-adaptive prototype of a CDSS for evaluating 95 
the severity of AD of an individual on a continuous spectrum. In order to achieve this, we first 96 
utilize a suite of machine learning techniques to extract useful information from large volumes 97 
of patient data and provide a disease outcome prediction for different types and combinations 98 
of AD markers. We demonstrate that CFA can reliably and accurately provide prediction of AD 99 
severity. Next, we design a CDSS that incorporates an automated computational approach for 100 
data pre-processing, modelling, and validation and uses selected CFA scores as data input. 101 
Since our system was designed to utilize information from readily available and cost-effective 102 
CFA markers, it can be easily implemented in general clinical practice.  103 
 104 
  105 
2. Material and methods 106 
2.1    Development of a computational framework 107 
2.1.1 Participants 108 
Patient records from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database 109 
(adni.loni.usc.edu) were used to develop the computational approach for evaluating the 110 
cognitive decline of an individual associated with AD. The primary goal of ADNI has been to 111 
test whether MRI, PET, other biological markers, and clinical and neuropsychological 112 
assessments can be combined to measure the progression of mild cognitive impairment (MCI) 113 
and early AD.  114 
The Clinical Dementia Rating Sum of Boxes (CDRSB) scores of 488 patients with a complete 115 
dataset of structural MRI and PET imaging, CSF biomarkers, CFA scores, socio-demographic 116 
features and medical history were used to describe AD staging and acted as an outcome 117 
(response) measure in prediction models. The CDRSB score is widely accepted in the clinical 118 
setting as a reliable and objective AD assessment tool (Cedarbaum et al., 2013). In total, we 119 
identified 178 cognitively healthy controls (CDRSB = 0), 263 subjects with questionable 120 
cognitive impairment (QCI) (0.5  CDRSB  4.0), 46 patients with mild AD (4.5  CDRSB  121 
9.0), and 1 patient with moderate AD (9.5  CDRSB  15.5). Since only one patient with 122 
moderate AD was identified, the subjects from mild and moderate AD categories were 123 
combined into one mild/moderate AD category.  124 
2.1.2 Data types 125 
We considered 66 features as potential predictors of cognitive decline associated with AD 126 
including 38 assessments/biomarkers (10 clinical and 28 biological measures) and 28 risk 127 
factors (family history, medical history, and sociodemographic characteristics). The cognitive 128 
and functional assessments offered information on memory deficits and behavioural 129 
symptoms of AD, CSF measures corresponded to the pathological changes at the biological 130 
level, while neuroimaging features allowed us to evaluate the neural degeneration related to 131 
AD. Sociodemographic, family, and patient’s medical history data enabled the identification of 132 
risk factors associated with increased risk of developing AD. 133 
Clinical measures included: Mini-Mental State Examination (MMSE) (Folstein, Robins & 134 
Helzer, 1983); Alzheimer’s Disease Assessment Scale 13 (ADAS13) (Mohs et al., 1997); 135 
Montreal Cognitive Assessment (MoCA) (Nasreddine et al. 2005); Logical Memory – 136 
Immediate Recall (LIMMTOTAL) (Abikoff et al., 1987); Logical Memory – Delayed Recall 137 
(LDELTOTAL) (Abikoff et al., 1987); Rey Auditory Verbal Learning Test (RAVLT): Immediate, 138 
Learning, Forgetting, and Perc Forgetting (Rey, 1964); and Functional Assessment 139 
Questionnaire (FAQ) (Pfeffer, Kurosaki, Harrah Jr, Chance & Filos, 1982).  140 
Biological data consisted of neuroimaging measurements and CSF biomarkers. Neuroimaging 141 
measures utilized MRI and PET (FDG and 18F-AV-45) data. MRI measures included 142 
volumetric data of hippocampus, ventricles, entorhinal, fusiform gyrus, middle temporal gyrus 143 
(MidTemp), whole brain, and intracerebral volume (ICV). The regional brain volumes were 144 
normalized by ICV. We also considered the volumetric data of intracranial gray matter 145 
(GRAY), white matter (WHITE), cerebrospinal fluid (CSF_V), and white matter 146 
hyperintensities (WHITMATHYP). Furthermore, two Boundary Shift Integral (BSI) measures 147 
were evaluated: whole brain (BRAINVOL) and ventricle (VENTVOL). Finally, we analysed the 148 
Florbetapir summary data represented by the gray matter regions of interest (frontal, 149 
anterior/posterior cingulate, lateral parietal, lateral temporal) normalized by the reference 150 
region of whole cerebellum (WHOLECEREBNORM). FDG-PET (FDG) was determined as a 151 
sum of mean glucose metabolism averaged across 5 regions of interest, i.e., right and left 152 
angular gyri (Angular Right and Temporal Left respectively), bilateral posterior cingulate 153 
(CingulumPost Bilateral), right and left inferior temporal gyri (Temporal Right and Temporal 154 
Left respectively) (Landau et al., 2011). Beside the composite FDG-PET, we also considered 155 
measurements for separate FDG-ROIs (i.e., Angular Right and Left, Temporal Right and Left, 156 
CingulumPost Bilateral) (Jagust et al., 2010). 18F-AV-45 PET (AV45) was represented by the 157 
mean of Florbetapir (F-18) standardized uptake value ratios (SUVR) of frontal, anterior and 158 
posterior cingulate, lateral parietal, and lateral temporal cortex (Landau et al., 2012). Other 159 
PET measures included spatial extent of hypometabolism determined using 3-dimensional 160 
stereotactic surface projection analysis (SUMZ2, SUMZ3) (Chen et al., 2010). In addition, CSF 161 
concentrations of total tau protein - t-tau (TAU), amyloid-β peptide of 42 amino acids - Aβ1–42 162 
(ABETA), and phosphorylated tau - p-tau181p (PTAU) were studied, as were ratios of t-tau to 163 
Aβ1–42 (TAU_ABETA), and p-tau181p to Aβ1–42 (PTAU_ABETA). The complete overview of data 164 
types used in our study and their abbreviations are shown in Table A.1.  165 
2.1.3      Feature selection and modelling approach 166 
The development of the computational framework consists of several steps. First, we 167 
conducted feature standardization to assimilate clinical measurements of diverse scales (Liu 168 
& Motoda, 2007). Accordingly, all features were rescaled so that they had the properties of a 169 
standard normal distribution with a mean of 0 and a standard deviation of 1 (Liu & Motoda, 170 
2007). The full dataset was then split into a model development set (90%) and a testing set 171 
(10%) was used for evaluating and comparing performances of competing models. The model 172 
development set was further split into training and validation sets (Barber, 2012). The training 173 
data was used to predict the responses for the observations in the validation set (Barber, 174 
2012). This provided us with an unbiased evaluation of a model fit on the training dataset while 175 
tuning the hyperparameters of the model. For the validation procedure, we used the leave-176 
one-out cross validation (LOOCV), which is a k-fold validation where k = n (Elisseeff & Pontil, 177 
2003). The final model evaluation was conducted on a held-out testing set that has not been 178 
used prior, either for training the model or tuning the model’s parameters. 179 
Since machine learning algorithms tend to produce biased models when dealing with 180 
imbalanced datasets, the Synthetic Minority oversampling technique (SMOTE) was used to 181 
handle the class imbalance in the model development set by resampling original patient data 182 
and creating synthetic instances (Chawla, Bowyer, Hall & Kegelmeyer, 2002). For improved 183 
generalization performance of predictive models, feature selection was implemented to 184 
identify the most relevant subset of features for predicting AD severity. Three regression 185 
models (Kernel Ridge Regression (KRR), Support Vector Regression (SVR), and k-Nearest 186 
Neighbor Regression (kNNreg)) and three classification models (Support Vector Machine 187 
(SVM), Random Forest (RF), k-Nearest Neighbor Classification (kNNclass))  were developed 188 
and their performance tested for different modality types and their combinations. The selection 189 
of features that achieved high predictive accuracy for the best performing classification and 190 
regression model was later used as entry input for CDSS. A leave-one-out cross validation 191 
(LOOCV) was applied for hyper-parameters optimization. The overall procedure for model 192 
development and evaluation is shown in Fig. 1. 193 
 194 
Fig. 1. Overview of the model development and validation procedure. 195 
2.1.3.1      Feature selection  196 
Previous studies typically used the univariate filtering methods to filter out the least promising 197 
features before the development of a predictive model (Michalak & Kwaśnicka, 2006). 198 
However, such filtering approaches can prompt loss of relevant features that are meaningless 199 
by themselves but when considered together, can improve model performance (Perez-Riverol, 200 
Kuhn, Vizcaíno, Hitz & Audain, 2017). To overcome this, the wrapper methods can be applied 201 
to assess the importance of specific feature sets. It has been shown that wrappers obtain 202 
subsets with better performance than filters. Wrappers use a search procedure to generate 203 
and evaluate different subsets of features in the space of possible feature subsets by training 204 
and testing a specific classification model (Hira & Gillies, 2015). The commonly used 205 
classification algorithms for identifying the most relevant input variables are: Naïve Bayes 206 
(Cortizo & Giraldez, 2006, Panthong & Srivihok, 2015), SVM (Maldonado & Weber, 2009, 207 
Maldonado, Weber & Famili, 2009), Random Forest (Rodin et al., 2009), Bagging (Panthong 208 
& Srivihok, 2015), AdaBoost (Panthong & Srivihok, 2015), and Extreme Learning Machines 209 
(Benoít, Van Heeswijk, Miche, Verleysen & Lendasse, 2013). These classification techniques 210 
combined with a greedy search algorithm allow for finding the optimal number of features by 211 
iteratively selecting features based on the classifier performance (Bengio et al., 2003).  212 
Since ADNI dataset is characterized by high dimensionality that increases the complexity of 213 
computation and analysis, we used the feature selection technique that was found to minimize 214 
redundancy and allowed for identifying features with the highest relevance to the disease class 215 
(Granitto, Furlanello, Biasioli & Gasperi, 2006). As such, we applied the Recursive Feature 216 
Elimination (RFE) method coupled with Random Forest for measuring variable importance. 217 
The RFE technique has been widely applied in healthcare applications due to its efficiency in 218 
reducing the complexity (Li, Xie, & Liu, 2018). Furthermore, studies demonstrated that RF-219 
RFE outperformed SVM-RFE in finding small subsets of features with a high discrimination 220 
capability and required no parameter tuning to produce competitive results (Granitto, 221 
Furlanello, Biasioli & Gasperi, 2006).The RFE method with the 10-fold validation was applied 222 
on the model development set (Bengio et al., 2003). For better replicability, the 10-fold CV 223 
procedure was repeated 10 times with different partitions of the data to avoid any bias 224 
introduced by randomly partitioning dataset in the cross-validation. The RFE technique 225 
searched for the optimal combination of predictors (among all possible subsets) that 226 
maximized model performance through backward feature elimination based on the predictor 227 
importance measure as a ranking criterion. At each iteration, the Random Forest (RF) 228 
algorithm, incorporating a hierarchical decision tree structure was used to explore all possible 229 
subsets of the features and measure their importance with respect to the classification 230 
outcome (Gregorutti, Michel & Saint-Pierre, 2017). To assess the robustness of RFE-RF 231 
process in selecting optimal subset of features, we applied the RFE technique to another 232 
similar type of ensemble methods, namely, bootstrap aggregated (bagged) trees (RFE-BT) 233 
and compared their results (Panthong & Srivihok, 2015). As with RFE-RF, the RFE-BT 234 
performance was evaluated in a 10-fold cross-validation repeated five times with different split 235 
positions. 236 
2.1.3.2     Development of predictive models 237 
A number of ML techniques have been used for AD detection. Classification approaches have 238 
been derived using Random Forest (RF) (Gray et al., 2013, Sarica, Cerasa & Quattrone, 239 
2017), Logistic Regression (Barnes et al., 2010, Bauer, Cabral & Killiany, 2018, Chary et al. 240 
2013, Wolfsgruber et al., 2014), and SVM (Casanova, Hsu, & Espeland, 2015, Cui et al., 2011, 241 
Klöppel et al., 2008, Ritter et al., 2015, Weygandt et al., 2011). In particular, the SVM showed 242 
great promise in improving diagnosis and prognosis in AD, especially in the studies 243 
characterized by a relatively small number of participants and disparate and high-dimensional 244 
data types (Dyrba, Grothe, Kirste, & Teipel, 2015, Klöppel et al., 2008, Long, Chen, Jiang, 245 
Zhang, & Alzheimer’s Disease Neuroimaging Initiative, 2017, Magnin et al., 2009). 246 
Furthermore, the SVM often outperformed other machine learning algorithms used for AD 247 
classification (e.g. RF, logistic regression) (Samper-González et al., 2018, Tripoliti, Fotiadis, 248 
Argyropoulou, & Manis, 2010). 249 
Compared to the ML classification methods, regression approaches focus on the estimation 250 
of continuous clinical variables along the continuum of disease severity (Wang, Fan, Bhatt & 251 
Davatzikos, 2010). Several regression methods have been applied in AD studies (Duchesne, 252 
Caroli, Geroldi, Collins, & Frisoni, G. 2009, Duchesne, Caroli, Geroldi, Frisoni, & Collins, 2005, 253 
Youssofzadeh et al., 2017). However, linear regression models have been often ineffective in 254 
capturing nonlinear relationships between biomarkers (e.g. neuroimaging data) and cognitive 255 
scores, especially when limited training examples of high dimensionality were used (Duchesne 256 
et al., 2009). On the other hand, nonparametric kernel regression methods yielded relatively 257 
robust estimations of continuous variables with good generalization ability (Liu, Cao, Yang, & 258 
Zhao, 2018, Wang et al., 2010). Regularized regression techniques, such as Ridge 259 
Regression, performed especially well given high dimensional and colinear AD data (Teipel et 260 
al., 2017, Youssofzadeh et al., 2017). In addition, the Ridge Regression combined with the 261 
kernel trick demonstrated high predictive performance when applied to individual patient data 262 
(Youssofzadeh et al., 2017). 263 
Our study built upon earlier findings and used six different non-parametric methods for the 264 
development of predictive models, namely SVM, RF, and kNNclass for classification and KRR, 265 
SVR, and kNNreg for regression. For each selected technique, we tested a series of values for 266 
the tuning process with the optimal parameters determined based on the model performance. 267 
The results of the best performing regression and classification algorithms are presented in 268 
the main text; the results of the remaining methods can be found in the Supplementary 269 
Material (Supplementary Table A.2., A.3, and A.4). 270 
The distinction between regression and classification models was reflected in definition of the 271 
response variable (CDRSB). The  regression models predicted a numerical value from a range 272 
of continuous values (i.e., 0 < CDRSB < 15.5) while the classification models predicted the 273 
target class, i.e., ‘Normal’ (CDRSB = 0), ‘QCI’ (0.5  CDRSB  4.0), ‘Mild/Moderate’ (4.5  274 
CDRSB  15.5). Since the model performance greatly depends on the choice of a kernel 275 
function (Hainmueller & Hazlett, 2014, Matheny, Resnic, Arora & Ohno-Machado, 2007), we 276 
tested different types of kernels, i.e., linear, polynomial, and radial basis function, and selected 277 
the one that maximized the performance measure for each model type.  278 
2.1.3.2.1   Kernel Ridge Regression 279 
The KRR combines ridge regression with a kernel trick allowing for mapping the input space 280 
into a higher dimensional space of nonlinear functions of predictors (Murphy, 2014). The 281 
general form of the KRR is described by:  282 
𝑓(𝑥) =  ∑ 𝛼𝑗𝑘(𝑥, 𝑥
′)
𝑁𝑇
𝑗=1                                                 (1) 283 
where 𝑁𝑇 is the number of training points, 𝑘 is the kernel function, and  are the weights 284 
obtained through the minimization of the cost function: 285 
𝐶(𝛼) =  ∑ (𝑓𝑀𝐿(𝑥𝑗) −  𝑓𝑗)
2 +  𝜆𝛼𝑇𝐾𝛼
𝑁𝑇
𝑗=1                                    (2) 286 
where 𝛼 =  (𝛼1, … , 𝛼𝑁𝑇 )
𝑇, 𝐾 is the kernel matrix, and 𝜆 controls the amount of regularization 287 
applied to the model (Vu et al., 2015). The best performance of the KRR model was achieved 288 
by applying a radial basis function (RBF) kernel defined as: 289 
𝑘(𝑥, 𝑥′)𝛾
𝑟𝑎𝑑𝑖𝑎𝑙 = exp [−𝛾‖𝑥 − 𝑥′‖2]                                     (3) 290 
where 𝑥 and 𝑥′ are input vectors, and 𝛾 > 0 is a width parameter (Murphy, 2014).  291 
2.1.3.2.2    Support Vector Machine and Support Vector Regression 292 
SVM is a classification technique that performs classification tasks by mapping the input 293 
vectors onto a higher dimensional space denoted as Φ: Rd → Hf (d < f) where an optimal 294 
separating hyperplane is constructed using a kernel function 𝑘(𝑥𝑖, 𝑥𝑗) (Ramírez et al., 2013). 295 
The performance of the SVM classifier was maximized using a polynomial kernel:  296 
𝑘(𝑥𝑖 , 𝑥𝑗) 𝑐,𝑑
𝑝𝑜𝑙𝑦𝑛𝑜𝑚𝑖𝑎𝑙 =  (< 𝑥𝑖 , 𝑥𝑗 > + 𝑐)
𝑑                                        (4) 297 
where 𝑥𝑖  and 𝑥𝑗 are vectors in the input space, 𝑐 is a free parameter trading off the influence 298 
of higher-order versus lower-order terms in the polynomial, and 𝑑 is the degree of polynomial 299 
(Cortes & Vapnik, 1995).  300 
SVR is based on the same principles as SVM. In contrast to traditional regression techniques, 301 
SVR focuses on minimizing the bound of the generalization error instead of seeking to 302 
minimize the prediction error on the training set (training error) (Basak, Pal, & Patranabis, 303 
2007). The objective of SVR is to find a regression function, 𝑦 = 𝑓(𝑥), such as it predicts the 304 
outputs {y} corresponding to a new input-output set {(x, y)} which are drawn from the same 305 
underlying joint probability distribution as the training set g = {(𝑥1, 𝑦1), (𝑥2, 𝑦2), (𝑥𝑝, 𝑦𝑝)}, where 306 
𝑥𝑖𝜖 𝜐
𝑁 is the vector of input variables and 𝑦𝑖𝜖 𝜐 is the vector of  corresponding output values 307 
(Awad & Khanna, 2015). The basic concept of SVR is to non-linearly transform the original 308 
input space into a higher dimensional feature space and perform linear regression in this 309 
feature space by ε-insensitive loss (Awad & Khanna, 2015). The SVR ε-insensitive loss 310 
function penalizes misestimates that are farther than ε from the desired output. The ε 311 
parameter determines the width of the ε-insensitive region (tube) around the function; a lower 312 
tolerance for error is reflected in a smaller ε value. If the predicted value is within the ε-zone, 313 
the loss is zero. If the predicted value is located outside the ε-zone, the loss is defined by the 314 
magnitude of the difference between the predicted value and the ε radius (Awad & Khanna, 315 
2015). 2.1.3.2.3 k-Nearest Neighbors  316 
kNN is a non-parametric approach applied to both classification and regression problems. The 317 
prediction of values of any new data points uses the 'feature similarity' measure (Kramer, 318 
2013). Accordingly, given a predefined threshold for the rule (i.e. the k number of neighbors) 319 
a new point is assigned a value based on its distance to training examples. Here, the distance 320 
between two data points is determined using the normalized Euclidean distance function 321 
defined as: 322 
dist(A,B) = √
∑ (𝑥𝑖− 𝑦𝑖)2
𝑚
𝑖
𝑚
 323 
where A and B are represented by feature vectors A = (x1, x2, …, xm), B= (y1, y2, …, ym), and 324 
m is the dimensionality of the feature space (Kramer, 2013). The kNN classification assigns a 325 
class label of the majority of the k-nearest patterns in the feature space while the kNN 326 
regression calculates the mean of the function values of its k-nearest neighbors (Kramer, 327 
2013). 328 
2.1.3.2.4 Random Forest  329 
RF estimates the importance of features included in a model by constructing an ensemble of 330 
decision trees (Rodin et al., 2009). As a boosting type of algorithm, RF combines the efforts 331 
of an ensemble of weak classifiers to build a single, stronger classifier. It achieves it by training 332 
a specified number of decision trees using different partitions of the training set and conducting 333 
the following randomizing operations: 1) each tree is trained on a random bootstrap subset of 334 
the training data; 2) each node of a tree only uses a randomly selected subset of features. 335 
The trained decision trees then produce a single prediction by averaging the individual 336 
estimates from random subsamples of the data. More detail about the theory and mechanisms 337 
of RF is given in Breiman (2001). 338 
2.1.3.3      Model performance evaluation 339 
The optimal subset of features identified during the feature selection process was 340 
subsequently used for training the selected regression and classification models. Both types 341 
of models were developed using 90% of the original data. The values of hyper-parameters 342 
used in constructing the models were optimized by applying grid search with LOOCV on the 343 
training data (Elisseeff & Pontil, 2003). The LOOCV technique is N-fold cross-validation, where 344 
N is the number of instances in the dataset. Although LOOCV is computationally intensive, 345 
choosing the number of folds equal to N gives more accurate assessment as the true size of 346 
the training set is closely mimicked and hence, the model bias is minimized (Elisseeff & Pontil, 347 
2003). Accordingly, we tested each single held out patient record (validation set) on the 348 
classifier trained on the remaining (N - 1) patient observations. Note that, the optimal values 349 
of the parameters were determined separately for each model type and each modality type or 350 
their combinations (i.e., CFA, MRI, PET, CSF, Age). The predictive performance of trained 351 
models was later evaluated on an (unseen) test set randomly partitioned from the original data 352 
(10% of the original data). The test was performed once for each model constructed using 353 
different modality types and their combinations. This allowed us to identify a subset of features 354 
that was later used as entry input for the CDSS. 355 
Two established measures for assessing the performance of regression models were used: 356 
the adjusted coefficient of determination (R2) and the Root Mean Square Error (RMSE) (Allen, 357 
1997). For classification models, we calculated four metrics: multi-class classification accuracy 358 
(MCA), sensitivity, specificity, and area under the ROC curve (AUC) (Hand & Till, 2001). Since 359 
simple form of AUC is only used as a binary classification measure, we extended the definition 360 
of AUC to the case of multi-class problem by averaging pairwise comparisons (Hand &Till, 361 
2001). 362 
2.2      Development of clinical decision support system 363 
The development of the computational framework described above allowed us to identify a 364 
subset of features with high discriminative power in evaluating levels of cognitive impairment 365 
in AD. These features were used as CDSS inputs for assessing AD severity of an individual 366 
(Bucholc et al. 2017, Bucholc et al., 2018). The CDSS workflow characteristics are shown in 367 
Fig. 2. The elements of the framework responsible for data pre-processing, modelling, and 368 
validation were automated and realized in the CDSS. The software prototype was developed 369 
using R version 3.4.1 and Shiny version 1.0.5. A team of domain experts including computer 370 
scientists and clinical experts was involved in the design process. To maximize system 371 
effectiveness, clarity, and guarantee efficient interaction with clinical staff, the visual 372 
representations of clinical data were displayed in concise formats that did not lower cognitive 373 
effort required to interpret them in a timely manner. Consultations with medical personnel 374 
enabled an understanding of the local context in which the system will be implemented. 375 
Furthermore, all involved parties became familiar with the rationale and methodological 376 
approach behind the development of our decision support tool. This closed-loop process 377 
between the computer scientist and clinicians helped us identify leading obstacles to the 378 
system’s adoption and routine use in clinical practice. 379 
 380 
Fig. 2. UML activity diagram of the computer-based clinical decision support system for 381 
predicting AD severity of an individual. 382 
3. Results 383 
3.1   Identification of AD features for the CDSS data entry  384 
3.1.1 Dimensionality reduction of AD data  385 
Both feature selection methods (RFE-RF and RFE-BT) we consider are variants of the 386 
recursive stepwise selection approach. Fig. 3 shows the performance profile across different 387 
subset sizes evaluated with the RFE-RF (Fig. 3A) and RFE-BT (Fig. 3B) techniques. The 388 
plotted values refer to the average accuracy measured using 10 repeats of 10-fold cross-389 
validation. The accuracy of classifiers (RF and BT) was calculated for different combinations 390 
of features and the subset of features with best performance was retained.  391 
Given the RFE-RF, we found a combination of 21 features (LDELTOTAL, FAQ, MOCA, 392 
ADAS13, LIMMTOTAL, RAVLT Immediate, MMSE, Hippocampus, FDG, Angular Left, Whole 393 
Brain, Age, RAVLT Perc Forgetting, MidTemp, Angular Right, Temporal Left, SUMZ3, RAVLT 394 
Learning, TAU_ABETA, TAU, Entorhinal) to achieve the highest predictive accuracy (MCA = 395 
88.9%, 95%CI = (88.2%, 89.6%)). The optimal subset of features identified with RFE-BT 396 
consisted of 18 features with MCA = 88.5%, 95%CI = (87.5%, 89.5%). All features (with the 397 
exception of SUMZ2) selected during the RFE-BT process were also identified with RFE-RF. 398 
Since the best subset of features determined using the RFE-RF approach was more 399 
comprehensive and yielded higher accuracy, we henceforth used it for training regression and 400 
classification models.  401 
The features identified with RF-RFE were grouped into five modality types: 1) CFA 402 
(LDELTOTAL, FAQ, MOCA, ADAS13, LIMMTOTAL, MMSE, RAVLT Immediate, RAVLT Perc 403 
Forgetting, RAVLT Learning); 2) MRI (Hippocampus, MidTemp, Entorhinal, Whole Brain); 3) 404 
PET (FDG, Angular Left, Angular Right, Temporal Left, SUMZ3); 4) CSF (TAU_ABETA, TAU); 405 
and 5) Age. The reason for grouping the features into modality types was to determine if cost-406 
effective and non-invasive AD markers, and therefore, easier to implement into the CDSS, 407 
have high discriminative power in assessing the severity of AD. Accordingly, we analysed the 408 
performance of predictive models constructed using each data type (as well as their 409 
combinations). 410 
 411 
Fig. 3. A) Performance profile across different subset sizes evaluated using the RFE-RF 412 
technique. Dark blue dot: the subset of features with the best performance B) Resampling 413 
performance of the best subset of features across different folds. 414 
3.1.2     Model performance 415 
To test the robustness of our hypothesis, we used six different ML methods for the 416 
development of predictive models, namely KRR, SVR, and kNNreg for regression and SVM, 417 
RF, and kNNclass for classification. Our analysis showed that all models incorporating CFA into 418 
their design performed better than models based on a single or combination of biomarkers. 419 
The results of the best performing regression and classification models (KRR and SVM 420 
respectively) were presented in the main text while the performance measures for the 421 
remaining 4 models were included in the Supplementary Material (Table A.2, A.3, A.4). 422 
3.1.2.1   Kernel Ridge Regression model 423 
The KRR model constructed for a combination of CFA and biomarkers performed consistently 424 
better than models incorporating only biomarkers (either a single modality type  425 
Table 1. KRR model performance measures for MRI, PET, CSF and cognitive function 426 
modalities retained for the training after feature selection. CFA represents 9 selected cognitive 427 
and functional assessments (LDELTOTAL, FAQ, MOCA, ADAS13, LIMMTOTAL, MMSE, 428 
RAVLT Immediate, RAVLT Perc Forgetting, RAVLT Learning), MRI - 4 features 429 
(Hippocampus, MidTemp, Entorhinal, Whole Brain), PET – 5 features (FDG, Angular Left, 430 
Angular Right, Temporal Left, SUMZ3), and CSF – 2 features (TAU_ABETA, TAU). ‘All’ 431 
features refer to a combination of MRI, PET, CSF, CFA, and Age. Performances of predictive 432 
models for each combination of modalities were recorded using an (unseen) testing set 433 
partitioned from the original data (10% of the original data). R2: adjusted coefficient of 434 
determination; RMSE: Root Mean Square Error. Asterix (*): a subset of features with the 435 
highest R2. For more details on data types and their abbreviations, refer to Table A.1. 436 
Features R2 RMSE 
All 0.839, 95%CI (0.793,0.885) 0.463 
CFA, PET, MRI, CSF 0.847, 95%CI (0.802,0.892) 0.442 
CFA, PET, MRI 0.839, 95%CI (0.788,0.890) 0.436 
CFA, PET, CSF 0.850, 95%CI (0.798,0.903) 0.400 
CFA, MRI, CSF 0.865, 95%CI (0.817,0.913) 0.402 
PET, MRI, CSF 0.417, 95%CI (0.256,0.578) 0.795 
CFA, PET 0.821, 95%CI (0.757,0.884) 0.429 
CFA, MRI * 0.874, 95%CI (0.827,0.922) 0.379 
CFA, CSF 0.863, 95%CI (0.809,0.918) 0.374 
PET, MRI 0.407, 95%CI (0.237,0.578) 0.800 
PET, CSF 0.374, 95%CI (0.192,0.555) 0.860 
MRI, CSF 0.181, 95%CI (0.012,0.351) 0.942 
CFA 0.866, 95%CI (0.809,0.922) 0.369 
PET 0.404, 95%CI (0.215,0.593) 0.810 
MRI 0.317, 95%CI (0.120,0.513) 0.854 
CSF 0.024, 95%CI (0,0.105) 1.215 
Age 0.055, 95%CI (0,0.176) 1.036 
Set of 4 cognitive/functional 
assessments (FAQ, ADAS13, 
MoCA, MMSE) 
0.832, 95%CI (0.754,0.910) 0.423 
or their  combinations) (Table 1). The best performance of the KRR model was observed for 437 
the combined CFA and MRI data, i.e., R2 = 0.874, 95%CI = (0.827, 0.922) (Table 1, bold). Of 438 
the two modalities, CFA features were the most discriminative while MRI markers provided 439 
complementary information about AD severity, enhancing the predictive performance of the 440 
model. Taken together, CFA provided insight into the memory deficits and behavioural 441 
symptoms of AD while MRI features offered complementary information regarding the 442 
structural degeneration of AD. Biomarker features achieved significantly lower performance, 443 
e.g., combined PET, MRI, and CSF data yielded R2 = 0.417, 95%CI = (0.256, 0.578) while for 444 
PET and MRI features, we reported R2 of 0.407, 95%CI = (0.237, 0.578). Given a single 445 
modality type, the model based on CFA (R2 = 0.866, 95%CI = (0.809, 0.922)) clearly 446 
outperformed models constructed with MRI (R2 = 0.317, 95%CI = (0.120, 0.513)), PET (R2 = 447 
0.404, 95%CI = (0.215, 0.593)) and CSF (R2 = 0.024, 95%CI = (0, 0.105)) features. Modelsbuilt 448 
using Age or CSF data alone achieved the worst performance. KRR predictions of AD severity 449 
of individual patients along with the expected diagnosis for each modality type are shown in 450 
Fig. 4. 451 
 452 
Fig. 4. KRR model predictions of medical diagnosis (CDRSB) of individual patients for 5 453 
modality types: a) CFA, b) MRI, c) PET, d) CSF, and e) Age. Blue dots: observed values of 454 
CDRSB; red dots: predicted values of CDRSB; vertical lines: differences between observed 455 
and predicted values of the outcome. Models’ predictions for each set of considered markers 456 
were obtained using an (unseen) testing set partitioned from the original data (10%). CFA: 457 
functional and cognitive assessments; MRI: magnetic resonance imaging; PET: positron 458 
emission tomography; CSF: cerebrospinal fluid biomarkers. 459 
Table 2. SVM model performance measures for MRI, PET, CSF and cognitive function modalities retained for the training after feature selection. CFA 460 
represents 9 selected cognitive and functional assessments (LDELTOTAL, FAQ, MOCA, ADAS13, LIMMTOTAL, RAVLT Immediate, MMSE, RAVLT Perc 461 
Forgetting, RAVLT Learning), MRI – 4 features (Hippocampus, MidTemp, Entorhinal, Whole Brain), PET – 5 features (FDG, Angular Left, Angular Right, 462 
Temporal Left, SUMZ3), and CSF – 2 features (TAU_ABETA, TAU). ‘All’ features refer to a combination of MRI, PET, CSF, CFA, and Age. Performances of 463 
predictive models for each combination of modalities were recorded using an (unseen) testing set partitioned from the original data (10% of the original data). 464 
MCA: multi-class classification accuracy. Multi-class AUC: multiclass area under the curve. Asterix (*): a subset of features with the best predictive performance. 465 
For more details on data types and their abbreviations, refer to Table A.1. 466 
Features MCA (%) 
Sensitivity (%) Specificity (%) Multi-class AUC  
(%) Normal QCI Mild/ Moderate Normal QCI Mild/ Moderate 
All  74.5, 95%CI (61.9,87.1) 82.4 65.4 100 80.0 85.7 93.0 91.6 
CFA, PET, MRI, CSF 80.9, 95%CI (69.5,92.2) 82.4 76.9 100 86.7 85.7 95.4 93.4 
CFA, PET, MRI 82.9, 95%CI (72.1,93.8) 82.4 80.8 100 90.0 85.7 95.4 94.1 
CFA, PET, CSF 80.9, 95%CI (69.5,92.2) 88.2 73.1 100 86.7 90.5 93.0 94.0 
CFA, MRI, CSF 72.3, 95%CI (59.4,85.3) 82.4 65.4 75.0 80.0 81.0 93.0 87.7 
PET, MRI, CSF 61.7, 95%CI (47.7,75.8)  70.6 57.7 50.0 60.0 71.4 100 72.5 
CFA, PET 80.9, 95%CI (69.5,92.2) 82.4 76.9 100 86.7 85.7 95.4 93.4 
CFA, MRI 76.6, 95%CI (64.4,88.8) 76.5 73.1 100 80.0 80.1 97.8 91.7 
CFA, CSF 76.6, 95%CI (64.4,88.8) 88.2 65.4 100 80.0 90.5 93.0 92.5 
PET, MRI 44.7, 95%CI (30.3,59.1) 58.8 34.6 50.0 43.3 61.9 97.8 67.7 
PET, CSF 46.8, 95%CI (32.4,61.2) 64.7 34.6 50.0 46.7 71.4 93.0 68.0 
MRI, CSF 53.2, 95%CI (38.8,67.6) 64.7 50.0 25.0 56.7 66.7 95.4 65.4 
CFA 76.6, 95%CI (64.4,88.8) 82.4 69.2 100 80.0 85.7 95.4 92.2 
PET 46.8, 95%CI (32.4,61.2) 70.6 26.9 75.0 43.3 80.1 90.7 71.7 
MRI 55.3, 95%CI (41.0,69.7) 82.4 34.6 50.0 50.0 90.1 90.1 73.5 
CSF 42.6, 95%CI (28.3,56.8) 64.7 23.1 75.0 56.7 85.7 74.4 68.6 
Age 40.4, 95%CI (26.2,54.6) 100 7.7 0 6.7 100 100 50.0 
Set of 4 cognitive/functional tests 
(FAQ, ADAS13, MoCA, MMSE)* 83.0, 95%CI (72.1,93.8) 100 69.2 100 76.7 100 97.7 94.9 
467 
3.1.2.2    Support Vector Machine 468 
Three target disease classes associated with AD severity were used in SVM classification: 469 
‘Normal’ (CDRSB = 0), ‘QCI’ (0.5  CDRSB  4.0), and ‘AD Mild/Moderate’ (4.5  CDRSB  470 
15.5). The SVM MCA and multiclass AUC observed for a combination of all 5 modality types 471 
was 74.5%, 95%CI = (61.9%, 87.1%) and 91.6% respectively (Table 2). Again, combinations 472 
of features incorporating CFA yielded higher performance than models constructed using a   473 
single or combined biomarker modalities. The best SVM performance was observed for a 474 
subset of 4 CFA features (FAQ, ADAS13, MoCA, MMSE), i.e., MCA of 83.0%, 95%CI = 475 
(72.1%, 93.8%) and AUC = 94.9% (Table 2, bold). Given individual modality types, the model 476 
built using CFA outperformed models constructed with MRI, PET, or CSF data. Fig. 5 shows 477 
the expected diagnosis along with the corresponding SVM predictions obtained for 5 478 
considered modality types. The best sensitivity and specificity in distinguishing Normal from 479 
QCI and Mild/Moderate AD cases was achieved for a combination of four CFA (FAQ, ADAS13, 480 
MoCA, MMSE) (sensitivity = 100% and specificity = 100%) (Table 2). The best sensitivity and 481 
specificity in identifying QCI from Normal and Mild/Moderate AD subjects was observed for 482 
combined CFA, PET, and MRI features (sensitivity = 80.8% and specificity = 85.7%). For all 483 
modality types (and their combinations), the QCI category had generally lower sensitivity than 484 
Normal and Mild/Moderate AD.  485 
3.2    Development of computer-based decision support tool 486 
Given the high predictive power of CFA and their common use in clinical practice, we 487 
developed a prototype of the CDSS for assessing the severity of AD of an individual (based 488 
solely on CFA) to aid clinicians to diagnose AD (Fig. 6). The feasibility of our CDSS was 489 
demonstrated by using the baseline data from ADNI to benchmark the ability of the AD severity 490 
score to model disease prediction. The system implements an automated machine learning 491 
approach for data pre-processing, modelling, and validation (as described in Section 2.1) and 492 
uses scores of selected cognitive measures as data entries. The disease outcome prediction 493 
 494 
Fig. 5. SVM model predictions of medical diagnosis of individual patients for 5 data types: a) 495 
CFA, b) MRI, c) PET, d) CSF, and e) Age. The vertical axis values and corresponding 496 
horizontal lines refer to the target CDRSB class, i.e., ‘Normal’ (green) = 0 (CDRSB = 0), ‘QCI’ 497 
(yellow) = 1 (0.5  CDRSB  4.0), and ‘Mild/Moderate’ (red) = 2 (4.5  CDRSB  15.5). Circles: 498 
predicted CDRSB class. CFA: functional and cognitive assessments; MRI: magnetic 499 
resonance imaging; PET: positron emission tomography; CSF: cerebrospinal fluid biomarkers. 500 
is generated using the KRR model as it regards the course of disease as a continuous 501 
progression and therefore, allows for discriminating between different ‘stages’ of the same AD 502 
category (e.g., a light-green colour in Fig. 6 indicates less probable QCI whereas a light-503 
orange colour - more probable QCI). Furthermore, the KRR model achieved the best predictive 504 
performance of all regression techniques considered. 505 
The input panel of our CDSS is designed for a set of 4 CFA inputs, namely, the total scores 506 
for FAQ, ADAS13, MoCA, and MMSE. These 4 efficient AD markers achieved the highest 507 
performance for the SVM model (MCA of 83%, 95%CI = (72.1%, 93.8%)) while for the KRR 508 
model, their performance (R2 = 0.832, 95%CI = (0.754,0.910)) was only slightly lower than 509 
best performance reported for the combined CFA and (more labour-intensive and costly) MRI 510 
data, i.e., R2 = 0.874, 95%CI = (0.827,0.922) (Table 1 & 2). Although all four tests are 511 
commonly used to provide a measure of cognitive impairment in clinical, research, and 512 
community settings, they have never been used in combination for evaluating AD severity 513 
(Nasreddine et al., 2006, Skinner et al., 2012, Teng et al., 2010, Trzepacz et al., 2015). The 514 
MMSE is currently the most widely used screening assessment for general cognitive 515 
evaluation and staging of Alzheimer’s disease (Nasreddine et al., 2006, Vertesi et al., 2001). 516 
It assesses various cognitive areas including attention, memory, language, orientation, and 517 
visuospatial abilities (Vertesi et al., 2001). The MMSE has been frequently applied not only to 518 
scale the severity of cognitive impairment at a given point in time but also to document the 519 
overall progression of cognitive decline over time (de Souza, Sarazin, Goetz, & Dubois, 2009). 520 
When compared to the MMSE, the MoCA consists of more memory, structured language, and 521 
executive function items and demonstrates high discriminant potential for MCI patients that 522 
performed within the normal range of the MMSE (Nasreddine et al., 2006, Trzepacz et al., 523 
2015, Whitney, Mossbarger, Herman, & Ibarra, 2012). In addition, the MoCA has been shown 524 
to exhibit superior sensitivity for amnestic MCI detection compared to the MMSE (Freitas, 525 
Simões, Alves, & Santana, 2013). The ADAS13 is mainly applied to evaluate the severity of 526 
cognitive and non-cognitive disfunctions from mild to severe AD (Skinner et al., 2012). 527 
However, it has also been used as an outcome measure for trials of interventions in people 528 
with MCI and appeared to be able to discriminate between patients with MCI and mild AD 529 
(Kueper, Speechley, & Montero-Odasso, 2018). In contrast to MMSE, MoCA, and ADAS13, 530 
the FAQ is not used in everyday clinical routine (Ritter et al., 2015). However, its relevance for 531 
determining impairment in everyday functioning and ensuring accurate early diagnosis of AD 532 
has been well-documented (Devanand et al., 2008, Ding et al., 2018, Ritter et al., 2015). For 533 
instance, studies found the use of FAQ can significantly contribute to discerning MCI versus 534 
AD cases with MoCA scores overlapping in the MCI range (Trzepacz et al., 2015). 535 
Furthermore, the FAQ has been shown to be highly sensitive in detecting differences in 536 
cognitive functioning between healthy and MCI patients, mainly via the assessment of the 537 
ability of assembling documents and remembering appointments (Jekel et al., 2015).  538 
Given the scores of 4 CFA described above, our system is able to provide an evidence-based 539 
AD score reflecting the severity of AD in the case of an individual subject. The score is 540 
generated by comparing selected CFA scores of an undiagnosed patient against a large 541 
database of existing patient records (Figs. 2 & 6). A single patient data with the predicted AD 542 
severity score is later added to the clinical data warehouse, updating the database, and 543 
initiating the retraining and validation procedure of the predictive model. To highlight the 544 
uncertainty inherent in the disease prediction, the system also provides a confidence interval 545 
for the predicted AD severity score based on the output from the individual sample validation 546 
procedure. Since our approach does not currently use input from clinicians for subsequent 547 
learning but uses its own predictions for reinforcing the existing model, further work is required 548 
to incorporate a self-training scheme that chooses only high-confidence predictions in the 549 
iterative process of model training. 550 
The CDSS patient profile includes only content that is relevant in the context of AD diagnosis, 551 
in a concise format to allow quick and unambiguous interpretation. It consists of: 1) the patient 552 
information section with patient’s medical, psychiatric, and personal history details (Fig. 6A); 553 
2) the AD severity measurement scale along with the predicted AD score and its confidence 554 
interval (Fig. 6B); and 3) CFA test scores together with their corresponding cut-off values for 555 
disease classes (Fig. 6C). The AD severity measurement scale is divided into 5 classes based 556 
on the CDRSB score i.e. ‘Normal’ (CDRSB = 0), ‘QCI’ (0.5  CDRSB  4.0), ‘AD Mild’ (4.0  557 
CDRSB  9), ‘AD Moderate’ (9.5  CDRSB  15.5)., and ‘AD severe’ (16  CDRSB  18). 558 
Simple and user-friendly layout of the patient profile allows clinicians to easily assess how 559 
different CFA contribute to the predicted AD severity score (Bucholc et al. 2018).  560 
4. Discussion  561 
In this study, we have developed a computational framework for identifying key measures in 562 
predicting the severity of AD using baseline data from ADNI, which leads to the development 563 
of an efficient and practical CDSS prototype for evaluating the severity of AD of an individual 564 
on a continuous spectrum. It is efficient in that only a small subset of the data attributes with 565 
the highest predictive accuracy of AD severity level is chosen, and they consist of readily 566 
available CFA scores. This is practical in the sense that clinical decisions of AD relies relatively 567 
heavily on CFA scores. Furthermore, the system uses an automated machine learning 568 
approach for data pre-processing, modelling, and validation, making the clinical decision 569 
process more objective and accurate. 570 
We showed that model predictions incorporating CFA were more accurate than those based 571 
solely on biomarker modalities (single or combinations) in this particular ADNI dataset. The 572 
KRR model performed best for the combined CFA and MRI data, i.e., R2 = 0.874, 95%CI = 573 
(0.827, 0.922) (Table 1). However, the KRR model incorporating only CFA scores (FAQ, 574 
ADAS13, MoCA, MMSE) achieved comparable performance, i.e., R2 = 0.832, 95%CI = (0.754, 575 
0.910). The SVR achieved the highest performance for the combination of CFA and MRI, i.e., 576 
R2 = 0.790, 95%CI (0.715, 0.866) while kNNreg performed best for CFA, i.e., R
2 = 0.750, 95%CI 577 
(0.653,0.847) (Table A.2). Given the SVM model, the optimal performance was reported for 578 
CFA data, i.e., MCA of 83.0%, 95%CI = (72.1%, 93.8%) for a subset of 4 CFA (FAQ, ADAS13, 579 
MoCA, MMSE) (Table 2). Again, the highest accuracy of the RF model was reported for all 580 
 581 
Fig. 6. Graphical user interface of the computer-based clinical decision support system for 582 
predicting severity of dementia of an individual patient. A) Patient information panel; B) AD 583 
severity measurement scale with AD severity score (black line) and its confidence interval 584 
(gray range); C) Measurement scales for the selected cognitive/functional assessments (FAQ, 585 
ADAS13, MoCA, MMSE). To allow quick interpretation, the AD severity measurement scale 586 
is divided into 5 classes based on the CDRSB score, i.e., ‘Normal’ (CDRSB = 0), ‘QCI’ (0.5  587 
CDRSB  4.0), ‘AD Mild’ (4.0  CDRSB  9), ‘AD Moderate’ (9.5  CDRSB  15.5)., and ‘AD 588 
severe’ (16  CDRSB  18).” 589 
CFA with MCA of 80.0%, 95%CI (66.7%, 90.9%) while kNNclass performed best for the 590 
combinations of CFA, MRI and CSF, i.e., MCA of 89.7%, 95%CI (76.9%,  96.5%) (Table A.3, 591 
A.4). These results lend support to existing clinical practices that depend relatively heavily on 592 
CFAs (Grober, Wakefield, Ehrlich, Mabie & Lipton, 2017). Future analysis of individual tasks 593 
making up each of the considered CFAs can lead to building a single optimised CFA. 594 
High predictive power of CFA has been demonstrated in previous studies (Chapman et al., 595 
2011, Cui et al., 2011, Korolev et al. , 2016). Cui et al. (2011) showed that single-modality 596 
predictive models based on CFA, namely FAQ, LM Delayed Recall, LM Immediate Recall, 597 
AVLT Delayed Recall and AVLT trials 1–5 (accuracy of 65%) outperformed those based on 598 
volumetric based CSF (accuracy of 60%) and MRI (accuracy of 62%) biomarkers in the task 599 
of early identification of MCI patients at risk of progressing to AD. In addition, incorporating 600 
multiple data modalities into the model, i.e., CFA, MRI, and CSF data, only slightly improved 601 
model performance (accuracy of 67%). Similar observations have been reported by (Chapman 602 
et al., 2011, Ewers et al., 2012). Cognitive measures (either alone or combined with other 603 
predictors) were also highly predictive in discriminating between stages of cognitive decline 604 
(Ewers et al., 2012, Nestor, Scheltens, & Hodges, 2004). In Ewers et al. (2012), the best 605 
statistical differentiation between AD and healthy subjects was reached for a combination of 606 
neuropsychological tests (RAVLT Immediate and RAVLT Delayed Recall) and CSF t-tau/Aβ1-607 
4 ratio. However, a single-modality model incorporating cognitive measures showed a 608 
predictive accuracy comparable to that of the multi-predictor model. Few other studies claimed 609 
relatively good predictive performance of models constructed using tests for memory 610 
impairment, abstract reasoning, and verbal fluency (Jacobs et al., 1995, Small, Herlitz, 611 
Fratiglioni, Almkvist, & Bäckman, 1997). Note that an increasing number of studies is based 612 
on the multimodal approach for either differentiating between stages of disease severity or 613 
identifying potential descriptors for the decline of cognition from MCI to AD (Bauer, Cabral, & 614 
Killiany, 2018, Ritter et al., 2015). Therefore, it is difficult to assess the individual contributions 615 
of modalities, such as CFA, to the accuracy of predictive models. Furthermore, differences in 616 
study designs reflected in different data types used, characteristics of patient populations, 617 
subject inclusion/exclusion criteria, diagnostic criteria for AD, classification frameworks and 618 
evaluation metrics make it challenging to compare results across studies. However, the 619 
discriminatory value of cognitive measures in the AD severity assessment or MCI-to-AD 620 
conversion has been repeatedly demonstrated. 621 
Numerous predictive approaches have been developed for diagnosis of AD, most of them 622 
derived using Cox Regression (Barnes et al., 2014, Derby et al., 2013, Ewers et al., 2012, 623 
Okereke et al., 2012, Seshadri et al., 2010), and Logistic Regression (Barnes et al., 2010, 624 
Bauer et al., 2018, Chary et al. 2013, Wolfsgruber et al., 2014). In the past decade, there has 625 
also been growing interest toward the application of SVM (Casanova et al., 2015, Cui et al., 626 
2011, Klöppel et al., 2008, Ritter et al., 2015, Weygandt et al., 2011), RF (Gray et al., 2013, 627 
Sarica et al., 2017) as well as deep neural network models for AD diagnostics (Ortiz, Munilla, 628 
Gorriz, & Ramirez, 2016, Shen, Wu, & Suk, 2017). The SVM-based models have been 629 
developed for both differential diagnosis and assessment of AD severity using neuroimaging, 630 
genome-based, and blood-based biomarkers (Klöppel et al., 2008, Laske et al., 2011, Smith-631 
Vikos & Slack, 2013, Weygandt et al., 2011). RF demonstrated advantages over other ML 632 
methods regarding the ability to handle highly non-linearly correlated data (Caruana & 633 
Niculescu-Mizil, 2006). While most of deep learning models show great performance in 634 
diagnostic classification, their interpretation remains an emerging field of research (Che, 635 
Purushotham, Khemani, & Liu, 2016). Other machine learning approaches for assisted 636 
diagnosis of cognitive impairment and dementia include linear regression (Agosta et al., 2012, 637 
Bauer et al., 2018, Koch et al., 2012), penalized regression (Wang, Liu, & Shen, 2018), 638 
Bayesian networks (Ding et al., 2018), hidden Markov models (Wang et al., 2014), and 639 
probabilistic multiple kernel learning (MKL) classifiers (Korolev et al., 2016, Youssofzadeh et 640 
al., 2017). Despite the common use of machine learning techniques for the disease 641 
diagnostics, controversy still exists regarding the effects of different combinations of 642 
explanatory variables, hyper-parameter tuning, sample size and class balance on the 643 
performance of predictive models (Du, Fu, & Calhoun, 2018, Finch & Schneider, 2007, Michie, 644 
Spiegelhalter, & Taylor, 1994). Different applications using different data sets (simulated or 645 
real) have failed to generate a model that performed best in all applications (Michie wt al., 646 
1994, Wolpert & MacReady (1997). The results of empirical comparisons often showed 647 
opposite results, for example one study claiming that decision trees are superior to neural 648 
nets, and another making the opposite claim (Michie et al., 1994). In fact, Wolpert & MacReady 649 
(1997) demonstrated the danger of comparing performance of algorithms on a small sample 650 
of problems and showed the best learning algorithm is always context dependant. 651 
The integration of efficient, less invasive, and cost-effective clinical markers into CDSS for AD 652 
diagnosis of individuals can support prevention-related decision-making in clinical settings. So 653 
far, educational interventions aimed at improving GPs’ knowledge and skills in recognition and 654 
management of dementia made no significant impact on the number of dementia patients’ 655 
care reviews or newly diagnosed cases (Dodd et al., 2015). Despite this, the deployment of 656 
CDSSs for a routine use in AD diagnostics, especially those incorporating machine learning 657 
methodologies, is still very rare. Furthermore, CDSSs currently used in dementia decision-658 
making require information from expensive and labour-intensive biomarkers (e.g., PredictAD) 659 
(Antila et al., 2013) or make use of predictive methodologies based on binary classifications 660 
(e.g., CADi2 or CANTAB) (Fray, Robbins & Sahakian, 1996, Onoda & Yamaguchi, 2014). 661 
Such approaches are designed to differentiate between two disease categories, e.g., healthy 662 
patients and individuals with cognitive impairment. Our computational approach defines the 663 
disease in more realistic manner as a continuous progress rather than a sequence of discrete 664 
stages, conforming more to the pathology of the disease. Importantly, it also provides clinician 665 
with an estimate of prediction reliability by adopting a validation procedure appropriate for an 666 
individual participant data.  667 
Our study has several limitations worth noting. First, our CDSS prototype does not yet include 668 
a mechanism for handling missing data. Work is currently in progress to develop an automated 669 
approach for missing data imputation that will be later incorporated into the system. Second, 670 
the current version of our CDSS provides clinicians with the predicted AD severity score of an 671 
individual with the corresponding confidence interval and CFA test scores together with cut-672 
off values for disease classes; however, it does not provide any measures of predictive 673 
accuracy of the incorporated model or information regarding the relative importance of 674 
individual predictors in the model. We plan to address these issues in future work by making 675 
the model evaluation metrics available to clinicians. We also intend to provide the relative 676 
importance of individual features incorporated into the model based on the magnitude of 677 
standardized regression coefficients. The format of visual representations of performance 678 
metrics will be developed in consultation with clinical end-users. Third, the AD measurement 679 
scale in our CDSS covers all 5 disease classes i.e. ‘normal’, ‘QCI’, ‘mild’, ‘moderate’, and 680 
‘severe’. However, due to data unavailability, patients with the ‘severe’ type of AD have not 681 
been included into our model training set and therefore, such cases could not be learned from 682 
the data. The inclusion of the ‘severe’ disease class in the CDSS means the suitability of our 683 
KRR model for making predictions outside the range of data used to estimate the model must 684 
be further evaluated. The necessary follow-up step would be a testing phase, to establish the 685 
degree to which prediction for ‘severe’ cases is contextually valid and hence, clinically useful. 686 
This could be done when additional data for patients with the ‘severe’ AD type is obtained, for 687 
example from memory clinics.  688 
It is also worth noting that the current computational approach implemented into our CDSS is 689 
based on the iterative method for semi-supervised learning that uses its own predictions to 690 
assign AD severity labels to new (unlabelled) patient data. Accordingly, our CDSS does not 691 
use input from clinicians for subsequent learning of the predictive model but uses its own 692 
predictions to reinforce the current model. We are aware that this may have a tendency for 693 
the model to overfit. Hence, for future work, we plan to enhance our computational framework 694 
by incorporating a self-training algorithm for selecting only high-confidence predictions to a 695 
training set for the next iteration. Most importantly, we will develop interpretability of our 696 
models, either through development of algorithms to “peer” through the black box (Giudotti et 697 
al., 2018) or complementing with more interpretable models such as decision trees (Sokol & 698 
Flach, 2018). This will facilitate an easy explanation of system’s content and allow for 699 
adjustment/correction of the AD severity class based on feedback from clinicians. A dynamic, 700 
easily interpretable predictive model interacting with decision makers to re-estimate 701 
predictions according to new clinical information could increase the clinical value of our CDSS. 702 
Finally, we acknowledge that the proposed CDSS requires further real-time testing and 703 
validation in a clinical setting to enhance system’s reliability, stability and adoptability.  704 
5. Conclusion  705 
Our CDSS offers a platform to standardize diagnostics in AD and has the potential to address 706 
variations in the quality of GP services associated with the lack of experience or skills in 707 
dementia recognition. By taking full advantage of ML techniques, our system can develop, 708 
update, and visualize AD risk profiles of individual patients by utilizing only non-invasive and 709 
cost-effective AD markers. Although our CDSS has not been designed to provide a diagnosis, 710 
it can streamline a clinical workflow and assist with clinical decision-making. As our predictive, 711 
ML-based framework becomes more established and its performance better characterized 712 
and tested, it could be further upgraded to automate the care pathway for dementia. This 713 
process will require the active involvement of the medical community to ensure that developed 714 
algorithms are intelligently integrated into existing medical practice and are rigorously 715 
validated for clinical efficacy.  716 
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Table A.1. Data types and their abbreviations. 
 
Type Feature Abbreviation Type Feature Abbreviation 
S
o
c
io
-d
e
m
o
g
ra
p
h
ic
s
 &
 f
a
m
ily
 
h
is
to
ry
* 
Age Age 
N
e
u
ro
p
s
y
c
h
o
lo
g
ic
a
l/
fu
n
c
ti
o
n
a
l 
a
s
s
e
s
s
m
e
n
t 
AD assessment scale-13 ADAS13 
Gender PTGENDER Mini-mental state examination MMSE 
Education PTEDUCAT 
Functional activities 
questionnaire 
FAQ 
Ethnicity PTETHCAT Montreal Cognitive Assessment MoCA 
Race PTRACCAT 
Logical Memory Immediate 
Recall 
LIMMTOTAL 
Marital status PTMARRY Logical Memory Delayed Recall LDELTOTAL 
Dementia history from dad FHQDAD 
Rey auditory 
verbal learning 
test  
Immediate  RAVLT Immediate 
Dementia history from mom  FHQMOM 
Does the participant have any 
siblings? 
FHQSIB Learning RAVLT Learning 
M
e
d
ic
a
l 
h
is
to
ry
* 
Psychiatric MHPSYCH Forgetting RAVLT Forgetting 
Neurologic MH2NEURL 
Percentage 
Forgetting 
RAVLT Perc Forgetting 
Head, eyes, ears, nose and 
throat 
MH3HEAD 
P
E
T
 d
a
ta
 
FDG PET FDG 
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cingulate, lateral parietal, lateral 
temporal) divided by the whole 
cerebellum reference region 
WHOLECEREBNORM 
Phosphorylated tau (p-tau181p) PTAU Cerebrospinal fluid volume CSF_V 
Ratio of tau to Aβ1–42 TAU_ABETA Intracranial gray matter volume GRAY 
Ratio of p-tau181p to Aβ1–42 PTAU_ABETA 
Intracranial white matter volume WHITE 
White matter hyperintensities 
(WMH) volume 
WHITMATHYP 
* Medical and family history is either Yes or No. 
Table A.2. SVR and kNNreg model performance measures for MRI, PET, CSF and cognitive function 
modalities retained for the training after feature selection. CFA represents 9 selected cognitive and 
functional assessments (LDELTOTAL, FAQ, MOCA, ADAS13, LIMMTOTAL, MMSE, RAVLT Immediate, 
RAVLT Perc Forgetting, RAVLT Learning), MRI - 4 features (Hippocampus, MidTemp, Entorhinal, Whole 
Brain), PET – 5 features (FDG, Angular Left, Angular Right, Temporal Left, SUMZ3), and CSF – 2 features 
(TAU_ABETA, TAU). ‘All’ features refer to a combination of MRI, PET, CSF, CFA, and Age. Performances 
of predictive models for each combination of modalities were recorded using an (unseen) testing set 
partitioned from the original data (10% of the original data). R2: adjusted coefficient of determination; 
RMSE: Root Mean Square Error. Asterix (*): a subset of features with the highest R2. For more details on 
data types and their abbreviations, refer to Table A.1. 
 
Features 
SVR kNNreg 
R2 RMSE R2 RMSE 
All 0.723, 95%CI (0.649,0.796) 1.116 0.658, 95%CI (0.571,0.744) 1.223 
CFA, PET, MRI, CSF 0.736, 95%CI (0.662,0.809) 1.082 0.641, 95%CI (0.548,0.734) 1.274 
CFA, PET, MRI 0.747, 95%CI (0.671,0.823) 1.074 0.684, 95%CI (0.593,0.774) 1.208 
CFA, PET, CSF 0.789, 95%CI (0.720,0.858) 0.975 0.637, 95%CI (0.530,0.744) 1.277 
CFA, MRI, CSF 0.788, 95%CI (0.716,0.859) 1.010 0.723, 95%CI (0.633,0.812) 1.103 
PET, MRI, CSF 0.577, 95%CI (0.440,0.714) 1.428 0.348, 95%CI (0.184,0.512) 1.842 
CFA, PET 0.788, 95%CI (0.714,0.862) 0.985 0.662, 95%CI (0.555,0.770) 1.228 
CFA, MRI*  0.790, 95%CI (0.715,0.866) 1.004 0.738, 95%CI (0.647,0.829) 1.074 
CFA, CSF 0.767, 95%CI (0.680,0.854) 1.040 0.708, 95%CI (0.604,0.813) 1.131 
PET, MRI 0.436, 95%CI (0.268,0.603) 1.706 0.306, 95%CI (0.133,0.478) 1.920 
PET, CSF 0.257, 95%CI (0.079,0.435) 1.946 0.361, 95%CI (0.180,0.542) 1.703 
MRI, CSF 0.525, 95%CI (0.359,0.692) 1.537 0.480, 95%CI (0.306,0.654) 1.132 
CFA* 0.743, 95%CI (0.644,0.843) 1.059 0.750, 95%CI (0.653,0.847) 1.043 
PET 0.377, 95%CI (0.188,0.566) 1.720 0.328, 95%CI (0.137,0.518) 1.780 
MRI 0.475, 95%CI (0.292,0.658) 1.618 0.323, 95%CI (0.129,0.518) 1.788 
CSF 0.235, 95%CI (0.039,0.431) 1.962 0.093, 95%CI (0.000,0.239) 2.219 
Age 0.139, 95%CI (0.000,0.077) 2.148 0.013, 95%CI (0.000,0.074) 2.156 
Table A.3. RF model performance measures for MRI, PET, CSF and cognitive function modalities retained for the training after feature selection. 
CFA represents 9 selected cognitive and functional assessments (LDELTOTAL, FAQ, MOCA, ADAS13, LIMMTOTAL, RAVLT Immediate, MMSE, 
RAVLT Perc Forgetting, RAVLT Learning), MRI – 4 features (Hippocampus, MidTemp, Entorhinal, Whole Brain), PET – 5 features (FDG, Angular 
Left, Angular Right, Temporal Left, SUMZ3), and CSF – 2 features (TAU_ABETA, TAU). ‘All’ features refer to a combination of MRI, PET, CSF, 
CFA, and Age. Performances of predictive models for each combination of modalities were recorded using an (unseen) testing set partitioned 
from the original data (10% of the original data). MCA: multi-class classification accuracy. Multi-class AUC: multiclass area under the curve. 
Asterix (*): a subset of features with the best predictive performance. For more details on data types and their abbreviations, refer to Table A.1. 
 
Features MCA (%) 
Sensitivity (%) Specificity (%) Multi-class AUC  
(%) Normal QCI Mild/ Moderate Normal QCI Mild/ Moderate 
All  78.7, 95%CI (64.3,89.3) 82.4 80.8 50.0 83.3 76.2 100 85.7 
CFA, PET, MRI, CSF 74.5, 95%CI (59.7,86.1) 88.2 69.2 50.0 73.3 81.0 100 86.1 
CFA, PET, MRI 78.7, 95%CI (64.3,89.3) 82.4 80.8 50.0 83.3 76.2 100 85.7 
CFA, PET, CSF 72.3, 95%CI (57.4,84.4) 82.4 69.2 50.0 73.3 76.2 100 84.7 
CFA, MRI, CSF 72.3, 95%CI (57.4,84.4) 82.4 69.2 50.0 73.3 76.2 100 84.7 
PET, MRI, CSF 53.2, 95%CI (38.1,67.9)  76.5 42.3 25.0 50.0 66.7 100 78.2 
CFA, PET 76.6, 95%CI (62.0,87.7) 88.2 73.1 50.0 76.7 81.0 100 86.5 
CFA, MRI 76.6, 95%CI (62.0,87.7) 82.4 76.9 50.0 80.0 76.2 100 85.3 
CFA, CSF 76.6, 95%CI (62.0,87.7) 82.4 76.9 50.0 80.0 76.2 100 85.3 
PET, MRI 44.7, 95%CI (30.2,59.9) 82.4 26.9 0.0 40.0 66.7 97.7 76.9 
PET, CSF 53.2, 95%CI (38.1,67.9) 82.4 38.5 25.0 46.7 71.4 100 79.8 
MRI, CSF 46.8, 95%CI (32.1,61.9) 70.6 34.6 25.0 53.3 61.9 93.0 75.3 
CFA* 80.0, 95%CI (66.7,90.9) 88.2 80.8 50 83.3 81.0 100 87.1 
PET 51.1, 95%CI (36.1,65.9) 82.4 34.6 25.0 46.7 71.4 97.7 79.3 
MRI 48.9 95%CI (34.1,63.9) 70.6 38.5 25 50.0 66.7 95.3 67.8 
CSF 42.6, 95%CI (28.3,57.8) 64.7 19.2 100 63.3 85.7 69.8 78.3 
Age 38.3, 95%CI (24.5,53.6) 52.9 30.8 25 60.0 66.7 76.7 58.5 
 
Table A.4. kNNclass model performance measures for MRI, PET, CSF and cognitive function modalities retained for the training after feature 
selection. CFA represents 9 selected cognitive and functional assessments (LDELTOTAL, FAQ, MOCA, ADAS13, LIMMTOTAL, RAVLT 
Immediate, MMSE, RAVLT Perc Forgetting, RAVLT Learning), MRI – 4 features (Hippocampus, MidTemp, Entorhinal, Whole Brain), PET – 5 
features (FDG, Angular Left, Angular Right, Temporal Left, SUMZ3), and CSF – 2 features (TAU_ABETA, TAU). ‘All’ features refer to a 
combination of MRI, PET, CSF, CFA, and Age. Performances of predictive models for each combination of modalities were recorded using an 
(unseen) testing set partitioned from the original data (10% of the original data). MCA: multi-class classification accuracy. Multi-class AUC: 
multiclass area under the curve. Asterix (*): a subset of features with the best predictive performance. For more details on data types and their 
abbreviations, refer to Table A.1. 
Features MCA (%) 
Sensitivity (%) Specificity (%) Multi-class AUC  
(%) Normal QCI Mild/ Moderate Normal QCI Mild/ Moderate 
All  70.2, 95%CI (55.1, 82.7) 94.1 53.9 75.0 73.3 90.5 90.7 88.4 
CFA, PET, MRI, CSF 63.8, 95%CI (48.5,77.3) 82.4 50.0 75.0 70.0 81.0 90.7 85.7 
CFA, PET, MRI 78.7, 95%CI (64.3,89.3) 94.1 65.4 100 83.3 95.2 90.7 93.4 
CFA, PET, CSF 66.0, 95%CI (50.7,79.1) 64.7 61.5 100 73.3 71.4 95.3 88.2 
CFA, MRI, CSF* 89.7, 95%CI (76.9,96.5) 82.4 92.3 100 96.7 85.7 97.7 95.9 
PET, MRI, CSF 57.5, 95%CI (42.2,71.7) 76.5 42.3 75.0 56.7 85.7 90.7 74.6 
CFA, PET 61.7, 95%CI (46.4,75.5) 64.7 53.9 100 73.3 71.4 90.7 87.3 
CFA, MRI 89.4, 95%CI (76.9,96.5) 94.1 84.6 100 93.3 95.2 95.3 96.5 
CFA, CSF 72.3, 95%CI (57.4,84.4) 70.6 69.2 100 80.0 76.2 95.3 90.4 
PET, MRI 63.8, 95%CI (48.5,77.3) 82.4 53.9 50.0 70.0 85.7 88.4 73.5 
PET, CSF 48.9, 95%CI (34.1,63.9) 70.6 34.6 50.0 53.3 76.2 88.4 69.4 
MRI, CSF 59.6, 95%CI (44.3,73.6) 58.8 57.7 75.0 70.0 81.0 86.1 70.2 
CFA 76.6, 95%CI (62.0,87.7) 82.4 69.2 100 80.0 85.7 95.4 92.2 
PET 42.6, 95%CI (28.7,57.8) 58.8 30.8 50.0 56.7 61.9 86.1 73.9 
MRI 55.3, 95%CI (40.1,69.8) 64.7 46.2 75.0 73.3 81.0 79.1 72.1 
CSF 29.8, 95%CI (17.3,44.9) 41.2 19.2 50.0 63.3 61.9 67.4 60.3 
Age 53.2, 95%CI (38.1,67.9) 47.1 65.4 0.0 80.0 61.9 81.4 50.7 
 
